Genodermatoses. Part II: Other Hereditary Dermatologic Disease

2014 ◽  
pp. 253-312
Author(s):  
Gregory A. Hosler ◽  
Kathleen M. Murphy
Keyword(s):  
Dermatologic Disease

scholarly journals Tyrosine kinases in inflammatory dermatologic disease

2011 ◽  
Vol 65 (2) ◽  
pp. 389-403 ◽  
Author(s):  
Ricardo T. Paniagua ◽  
David F. Fiorentino ◽  
Lorinda Chung ◽  
William H. Robinson
Keyword(s):  
Tyrosine Kinases ◽  
Dermatologic Disease

International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update

2016 ◽  
Vol 43 (5) ◽  
pp. 959-960 ◽  
Author(s):  
Joseph F. Merola ◽  
April W. Armstrong ◽  
Ami Saraiya ◽  
John Latella ◽  
Amit Garg ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Outcome Measures ◽  
Treatment Efficacy ◽  
Regulatory Agencies ◽  
Washington Dc ◽  
Patient Centered ◽  
Psoriatic Disease ◽  
Disease Outcomes ◽  
Dermatologic Disease

Previous publications have described the International Dermatology Outcome Measures (IDEOM) group, comprising patients, physicians, health economists, participating pharmaceutical industry partners, payers, and regulatory agencies. The goal of IDEOM is to create patient-centered, validated measures of dermatologic disease progression and treatment efficacy for use in both clinical trials and clinical practice. We provide an update of IDEOM activities as of our 2015 IDEOM meeting in Washington, DC, USA.

scholarly journals Dermatoses Of Pregnancy: A Retrospective Cohort Study In Spain

2019 ◽  
Author(s):  
M. Gomes Ferreira ◽  
D. Bancalari Diaz ◽  
Á. De Dios Velázquez ◽  
J. Cañueto
Keyword(s):  
Mediterranean Population ◽  
Pemphigoid Gestationis ◽  
Skin Changes ◽  
Inflammatory Dermatoses ◽  
Polymorphic Eruption Of Pregnancy ◽  
Multiple Gestations ◽  
Nulliparous Women ◽  
Atopic Eruption Of Pregnancy ◽  
Dermatologic Disease ◽  
Dermatoses Of Pregnancy

Abstract Background: Dermatoses of pregnancy (DP) is a heterogeneous group of pruritic inflammatory dermatoses that occur exclusively during pregnancy and/or puerperium. The objective of this study was to assess the specific DP and non-specific dermatoses in a Mediterranean population living in Spain. Methods: This five-year retrospective study included 79 pregnant women with dermatologic disease from a total of 10533 pregnancies. Obstetric and clinical variables were assessed. Physiological skin changes of pregnancy were excluded. Those dermatoses that may also be observed beyond pregnancy and puerperium were also excluded. Results: The mean age was 32 years. The most common DP were: Polymorphic eruption of pregnancy (PEP) – 36%, Atopic eruption of pregnancy (AEP) – 26%, Intrahepatic cholestasis of pregnancy (ICP) – 8% and Pemphigoid gestationis (PG) – 6%. The other 24% presented non-specific dermatoses. Only in one case of PG the newborn showed comorbidity. Discussion: Multiple gestations were observed in 10,3% of PEP, in association with a rapid abdominal distention. In AEP, there was a predominance of nulliparous women in the second trimester of pregnancy, an atopic dermatitis background and female newborns. In PG, there was a majority of nulliparous in the second and third trimesters. PG was the only dermatoses associated to comorbidity of the newborn. In ICP, all patients had pruritus in the palms along with excoriations, with predominance of nulliparous and multiple gestations.

Junctional Epidermolysis Bullosa of the Larynx

PEDIATRICS ◽  
1986 ◽  
Vol 78 (1) ◽  
pp. 172-174
Author(s):  
MARGARET A. KENNA ◽  
SYLVAN E. STOOL ◽  
SUSAN B. MALLORY
Keyword(s):  
Case Report ◽  
Epidermolysis Bullosa ◽  
Minor Trauma ◽  
Junctional Epidermolysis Bullosa ◽  
First Case ◽  
New Variant ◽  
Genetically Determined ◽  
Dermatologic Disease ◽  
Hereditary Epidermolysis Bullosa ◽  
Laryngeal Involvement

Epidermolysis bullosa is a rare genetically determined, dermatologic disease in which minor trauma causes blister formation.1 A new variant of hereditary epidermolysis bullosa, generalized atrophic benign epidermolysis bullosa, junctional form, has been recently reported.2 Airway involvement has not been a notable feature of this disease. We report the first case of an infant having benign junctional epidermolysis bullosa with laryngeal involvement. CASE REPORT An 11-month-old white boy with known junctional epidermolysis bullosa and mild stridor since birth was referred by his dermatologist for increasing stridor of 24 hours duration. He was initially thought to have croup; however, conservative treatment with mist and racemic epinephrine did not improve his symptoms.

Off-Label Therapeutic Potential of Crisaborole

2020 ◽  
Vol 24 (3) ◽  
pp. 292-296 ◽  
Author(s):  
Caitlyn Makins ◽  
Ravina Sanghera ◽  
Parbeer S. Grewal
Keyword(s):  
Therapeutic Potential ◽  
Case Reports ◽  
Controlled Trial ◽  
Seborrheic Dermatitis ◽  
Off Label Use ◽  
Off Label ◽  
Therapeutic Uses ◽  
Adults And Children ◽  
Dermatologic Disease ◽  
Label Use

Crisaborole, a topical phosphodiesterase-4 inhibitor, was recently approved in 2016 for the treatment of mild to moderate atopic dermatitis in adults and children greater than 2 years of age. Since that time, several case reports and a small randomized controlled trial have been published regarding the off-label use of crisaborole for the treatment of other inflammatory dermatologic disorders. This paper reviews the current, albeit limited, evidence for off-label use of crisaborole for psoriasis, seborrheic dermatitis, vitiligo, and inflammatory linear verrucous epidermal nevus. Additional potential therapeutic uses for crisaborole are also postulated, based on its mechanism of action. Future studies are required to elucidate the full therapeutic potential of crisaborole; however, it is a welcome addition to the current nonsteroid topical treatments for inflammatory dermatologic disease.

Sign in / Sign up

Export Citation Format

Share Document